Antibodies targeting programmed cell death protein-1 (PD-1) or its ligand PD-L1 rescue T
cells from exhausted status and revive immune response against cancer cells. Based on the …

In China, lung cancer is a primary cancer type with high incidence and mortality. Risk factors
for lung cancer include tobacco use, family history, radiation exposure, and the presence of …

Objective To evaluate sintilimab versus placebo in combination with chemotherapy (cisplatin
plus paclitaxel or cisplatin plus 5-fluorouracil) as first line treatment of unresectable locally …

Background PD-1 inhibitor plus chemotherapy had been shown to be an effective first-line
treatment for patients with metastatic non-small-cell lung cancer (NSCLC). However, there …

Background A substantial proportion of patients with unresectable stage III non-small-cell
lung cancer (NSCLC) cannot either tolerate or access concurrent chemoradiotherapy, so …

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …

Introduction Camrelizumab, a humanized immunoglobulin G4-κ monoclonal antibody
against programmed cell death protein 1, has exhibited antitumor activity and tolerability …

Epidermal growth factor receptor (EGFR), the receptor for members of the epidermal growth
factor family, regulates cell proliferation and signal transduction; moreover, EGFR is related …

Lung cancer is the leading cause of cancer-related death across the world. Unlike lung
adenocarcinoma, patients with lung squamous cell carcinoma (LSCC) have not benefitted …

This randomized, open-label, multi-center phase 2 study (NCT03116152) assessed
sintilimab, a PD-1 inhibitor, versus chemotherapy in patients with esophageal squamous cell …